Drug Trial Radar · NCT04151212
A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 30, 2018
Primary completion
Feb 28, 2021
Study completion Apr 30, 2021
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Nov 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.
Conditions
- Age-related Macular Degeneration
Interventions
BAT5906 injectionDrug
Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT)Time frame: 2 weeks
- Maximum tolerated dosed(MTD)Time frame: 0-70days
- Area under the curve(AUC0-t, AUC0-inf)Time frame: 0-70days
- Maximum serum drug concentration(Cmax)Time frame: 0-70days
- Half-life period(t1/2)Time frame: 0-70days
- Maximum serum drug time(Tmax)Time frame: 0-70days
- Plasma clearance(CL)Time frame: 0-70days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.